my.bionity.com
With an accout for my.bionity.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
02-01-2012: The goal of the interdisciplinary research project PeTrA*, which is sponsored by the German Ministry for Education and Research (BMBF), is supersede the need for injections for biopharmaceuticals used e.g. in cancer immunotherapy by developing spray and tablet formulations which include innovative biofunctional polymers. The project is designed to simplify the administration of biopharmaceuticals and to improve their bioavailability. PeTrA is managed by a consortium consisting of Evonik Industries AG, Merck KGaA, EMC microcollections GmbH, a high-tech company for peptide and peptidomimetics synthesis, the Helmholtz Center for Infection Research (HZI), and the Fraunhofer Institute for Interfacial Engineering and Biotechnology (IGB).
The project, which started on July 1, 2011, is scheduled to last for three years. Approximately half of the 6 million Euro budget is supported by the three industry partners. The PeTrA consortium also includes the Friedrich Schiller University in Jena, the Saarland University, the University of Nijmegen (Netherlands), the Bonn University Hospital, the Charité Hospital Berlin, the Kiel University, and the Würzburg University.
Biopharmaceuticals have been on the advance for years in modern drug therapy. They include peptides, proteins and antibodies, nucleic acids and blood components that represent a promising basis for new active principles and for cancer immunotherapy. Many of these highly successful drugs improve patient life quality and have enormous technological potential for the pharmaceutical industry.
Today, biopharmaceuticals are mostly administered by injection. Indeed, there is no efficient or broadly applicable system for administering them via the mouth (oral) or through the respiratory pathways (inhalation) because they are not easily absorbed by the mucous membranes of the gastrointestinal tract and respiration system, and tend to be degraded in the stomach before they can have an effect on the body. The PeTrA project aims at overcoming these obstacles by packaging highly sensitive biopharmaceuticals into nano- and micro-sized particles that transport the active ingredients through the mucous membranes and protect them from degradation in the stomach.
“Tablets and sprays are more convenient for patients, particularly in long-term therapies which can require continuous drug intake over weeks or months,” says Dr. Rosario Lizio about the motivation of the research partners. Lizio, the PeTrA project coordinator, is also the head of the Discovery & Development department of Pharma Polymers, a product line of the Health Care Business Line of Evonik specialized in drug delivery systems.
“I am convinced that the breadth of expertise represented in the project provides an excellent basis for the development of novel drug delivery technologies for biopharmaceuticals.” says Lizio. “The team composition combines leading competencies in the design of pharmaceutical functional polymers, formulation of drug release systems as well as innovative models to assess the in-vivo efficacy of these systems. I am delighted to be part of this venture and look forward to contributing Evonik’s expertise in functional pharmaceutical polymer design and formulation” he adds.
*PeTrA stands for “Platform for efficient epithelial transport of pharmaceutical applications with innovative particular carrier systems” and is part of the BMBF grant project “Efficient drug transport in biological systems - BioMatVital: Biotransporters.“
Contact / Request information
Request further information free of charge:
Watchlist
This is where you can add this news to your personal favourites
Pieris Receives BMBF Grant to Fund PRS-110 c-Met Antagonist Anticalin Program
Pieris AG announced the receipt of a EUR 1 million grant to support the development of the company’s proprietary PRS-110 compound targeting c-Met, a cellular receptor that plays a key role in cancer cell growth and metastasis. The goal of the funded research will be to delineate a biomarker ... more
Exosome Diagnostics GmbH, a subsidiary of Exosome Diagnostics, Inc., and the Department of Dermatology at the Ludwig Maximilian University (LMU) announces the awarding of a EUR one million grant from the German Federal Ministry for Education and Research (BMBF) to develop blood-based diagno ... more
BMBF PeTrA Project to make administration of biopharmaceuticals more tolerable for patients
The goal of the interdisciplinary research project PeTrA*, which is sponsored by the German Ministry for Education and Research (BMBF), is supersede the need for injections for biopharmaceuticals used e.g. in cancer immunotherapy by developing spray and tablet formulations which include inn ... more
Bundesministerium für Bildung und Forschung (BMBF)
Education forms the basis for one's whole life; research opens up previously unknown opportunities in all fields of life. Education and research need perspectives which extend far into the future. These are the foundations on which our future evolves. The BMBF's promotion of education and r ... more
Evonik increases prices of cGMP-grade amino acids
Effective immediately, Evonik Industries is increasing the prices for the products L-Ornithine-L-Aspartate, L-Proline, L-Lysine salts, L-Methionine, L-Arginine-L-Aspartate, Glycine and all other cGMP-grade amino acids. The increase amounts to 10 – 20 percents and applies globally to all new ... more
BMBF PeTrA Project to make administration of biopharmaceuticals more tolerable for patients
The goal of the interdisciplinary research project PeTrA*, which is sponsored by the German Ministry for Education and Research (BMBF), is supersede the need for injections for biopharmaceuticals used e.g. in cancer immunotherapy by developing spray and tablet formulations which include inn ... more
Evonik Industries AG has set up a new laboratory at their Hanau site for highly potent active pharmaceutical ingredients (HPAPI) and expanded their cGMP capacity for HPAPI on a kilogram scale at Tippecanoe Laboratories (Lafayette, Indiana, USA). The new laboratory allows Evonik to develop a ... more
Q1/2012: Merck Total Revenues Increase 3.2% to € 2.6 Billion
“Merck delivered a reasonable operating performance in the face of a difficult year-over-year comparison,” said Karl-Ludwig Kley, Chairman of the Executive Board of Merck. “During the first quarter, we kicked off our efficiency program and announced the first planned initiatives as part of ... more
Merck PETACC-8 Study of Erbitux as Adjuvant Treatment in Colon Cancer Shows no Benefit
Merck announced results from an interim analysis of the Phase III clinical trial PETACC-81. The study investigated the potential clinical utility of Erbitux® (cetuximab) for the adjuvant treatment of stage III colon cancer after complete surgical removal of the primary tumor. The pre-specif ... more
Merck Announces Merck Serono Implementation Plans for Its Efficiency Program in Switzerland
Merck announced the efficiency measures it plans to take related to Merck Serono’s operations in Switzerland as part of the comprehensive transformation program announced by the company in February. Merck’s transformation program is focused on addressing unprecedented market shifts, increas ... more
Pyrodetect System: the Human(e) Alternative in Pyrogen Testing
A revolutionary test for the detection and quantification of pyrogens based on the monocyte activation test (MAT) more
ISOSLIDE® Reticulin control slides for histology
The ISOSLIDE® Reticulin Control Slides Box is a new product from Merck Millipore for the detection of reticulin fibers in histological tissue specimen more
Merck Millipore offers new, user-friendly packaging sizes for its microscopy products Entellan® new, Schiff´s reagent and OSTEOMOLL® more
Merck Millipore provides all expertise on chromatography in one place
With almost 400 pages, the catalog contains detailed information on a total of around 4,000 Merck Millipore chromatography products more
The Merck Group is a globally operating company in the areas of pharmaceuticals and chemicals. With 34,500 employees and more than 200 companies we are represented in 58 countries worldwide. Founded in 1668 in Darmstadt, Germany, the company sees the keys to success in entrepreneurial emplo ... more
Merck Schuchardt OHG, a 100% subsidiary of Merck KGaA, Germany, has, for the last 135 years, been one of the leading German producers and suppliers of organic intermediates, fine chemicals, reagents and solvents for laboratories, medium-sized and bulk production. more
Together EMD Biosciences and Merck Chemicals Ltd. are the research reagents group of the Performance and Life Science Chemicals division of Merck KGaA. Merck KGaA was founded in 1668 in Darmstadt, Germany, and now has more than 29,000 employees in 53 countries. EMD or Merck – why two names ... more
BMBF PeTrA Project to make administration of biopharmaceuticals more tolerable for patients
The goal of the interdisciplinary research project PeTrA*, which is sponsored by the German Ministry for Education and Research (BMBF), is supersede the need for injections for biopharmaceuticals used e.g. in cancer immunotherapy by developing spray and tablet formulations which include inn ... more
AFFiRiS atherosclerosis vaccine development receives EU support
AFFiRiS AG announced that its atherosclerosis vaccine development program is receiving support from the EU's EUROTRANS-BIO call. The supported project - known as CETP Vaccine (ETB-2008-28) - is based on the AFFITOME® technology of AFFiRiS AG and is being conducted together with EMC microcol ... more
Neuer Forschungsverbund entwickelt biokatalytische Verfahren zur Aktivierung von Kohlenwasserstoffen
Die BRAIN AG gibt den Abschluss eines Kooperationsvertrages mit den Hochschulgruppen um Prof. Dr. Andreas Schmid, Universität Dortmund, PD Dr. Jürgen Pleiss, Universität Stuttgart, Prof. Dr. Ulrich Schwaneberg, International University Bremen, der EMC microcollections GmbH und einem führend ... more
BMBF PeTrA Project to make administration of biopharmaceuticals more tolerable for patients
The goal of the interdisciplinary research project PeTrA*, which is sponsored by the German Ministry for Education and Research (BMBF), is supersede the need for injections for biopharmaceuticals used e.g. in cancer immunotherapy by developing spray and tablet formulations which include inn ... more
Using plasmas, sealed plastic bags can be modified at atmospheric pressure so that human cells can adhere to and reproduce on their walls. Cell culture bags of this kind are an important aid for research and clinical purposes and may eventually replace the Petri dishes used today. Physician ... more
The immune system's guard against cancer
The human body has developed various mechanisms, through which it can protect itself against newly-developing cancer cells. For instance, killer-cells recognize and destroy altered cells in our organs every day. Once tumours have developed, they may be inhibited in growth by messenger subst ... more
Helmholtz-Zentrum für Infektionsforschung GmbH
As a Helmholtz centre for infectious diseases, the main focus of the GBF research activities is to study microbial virulence factors, host-pathogen interactions, and immunity to develop strategies for the diagnosis, prevention and therapy of human infectious diseases. In addition, the GBF B ... more
Helmholtz-Zentrum für Infektionsforschung GmbH
How do bacteria, viruses, parasites and fungi make us sick? How does our immune system defend our body? These are the questions we at the HZI want to answer. Our goal: To set up the basis for new diagnostic tools, new active agents and new therapies against infectious diseases. Together wi ... more
BMBF PeTrA Project to make administration of biopharmaceuticals more tolerable for patients
The goal of the interdisciplinary research project PeTrA*, which is sponsored by the German Ministry for Education and Research (BMBF), is supersede the need for injections for biopharmaceuticals used e.g. in cancer immunotherapy by developing spray and tablet formulations which include inn ... more
First biogeneric therapeutic protein from Fraunhofer Institute introduced to the market
Interferon-beta is used for multiple sclerosis therapy. An interferon-beta protein developed at the Fraunhofer Institute for Interfacial Engineering and Biotechnology IGB, Stuttgart, Germany, in collaboration with CinnaGen company, Tehran, Iran, is now the first therapeutic protein from a F ... more
About CHEMIE.DE
CHEMIE.DE Information Service GmbH runs specialist scientific internet portals. The secret to our success? We are familiar with what we publish.
Advertising at CHEMIE.DE
Our advertising formats support you in getting your message across to a clearly defined target audience.
© 1997-2012 CHEMIE.DE Information Service GmbH, All rights reserved
